Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer
- 5 August 2022
- conference paper
- conference paper
- Published by Medicom Medische Uitgeverij BV in Medicom Conference Report ASCO 2022
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerThe New England Journal of Medicine, 2022
- Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter ExperienceJournal of the National Comprehensive Cancer Network, 2021